Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H49BrN6O9S |
| Molecular Weight | 869.821 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2C(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](NC(=O)OC4CCCC4)C(C)(C)C)C(=O)N[C@@]5(C[C@H]5C=C)C(O)=O)=CC(=NC2=C1Br)C6=CSC(NC(=O)C(C)C)=N6
InChI
InChIKey=LLGDPTDZOVKFDU-XUHJSTDZSA-N
InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor developed by Boehringer-Ingelheim for the treatment of hepatitis C. Faldaprevir in combination with pegylated interferon and ribavirin, or interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin provides high sustained virological response rates for HCV genotype 1 infection. The most common adverse events were gastrointestinal disorders, rash, and photosensitivity. The interferon-free combination of faldaprevir and deleobuvir with ribavirin was effective for HCV genotype 1 infection, although further improvements will still be needed. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J05AP04
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
||
|
WHO-ATC |
J05AE13
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB11808
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
9497
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
100000144871
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
958X4J301A
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL1241348
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
Faldaprevir
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
C171746
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
42601552
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
DTXSID20230084
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
801283-95-4
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
SUB121692
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY | |||
|
AB-19
Created by
admin on Wed Apr 02 07:07:46 GMT 2025 , Edited by admin on Wed Apr 02 07:07:46 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)